Abstract
Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys. Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb. Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 4E-BP1, resulting in uncontrolled cell growth and tumourigenesis. Despite recent promising genetic, diagnostic, and therapeutic advances in Tuberous Sclerosis Complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. In this review we will discuss and analyse all the important findings in the molecular pathogenesis of Tuberous Sclerosis Complex, focusing on genetics and the molecular mechanisms that define this multisystemic disorder.
Keywords: Tuberous sclerosis, tuberin, hamartin, mutations, genetics, multifactorial disease, germ-line mosaicism, rapamycin
Current Genomics
Title: Genetics and Molecular Biology of Tuberous Sclerosis Complex
Volume: 9 Issue: 7
Author(s): Valerio Napolioni and Paolo Curatolo
Affiliation:
Keywords: Tuberous sclerosis, tuberin, hamartin, mutations, genetics, multifactorial disease, germ-line mosaicism, rapamycin
Abstract: Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys. Tuberous Sclerosis Complex is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signalling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb. Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 4E-BP1, resulting in uncontrolled cell growth and tumourigenesis. Despite recent promising genetic, diagnostic, and therapeutic advances in Tuberous Sclerosis Complex, continuing research in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. In this review we will discuss and analyse all the important findings in the molecular pathogenesis of Tuberous Sclerosis Complex, focusing on genetics and the molecular mechanisms that define this multisystemic disorder.
Export Options
About this article
Cite this article as:
Napolioni Valerio and Curatolo Paolo, Genetics and Molecular Biology of Tuberous Sclerosis Complex, Current Genomics 2008; 9 (7) . https://dx.doi.org/10.2174/138920208786241243
DOI https://dx.doi.org/10.2174/138920208786241243 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myeloperoxidase as a Target for the Treatment of Inflammatory Syndromes: Mechanisms and Structure Activity Relationships of Inhibitors
Current Medicinal Chemistry Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Network Pharmacology-based Prediction and Verification of Shikonin for Treating Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting Cell Death in Tumors by Activating Caspases
Current Cancer Drug Targets Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design Non-Viral Gene Delivery Methods
Current Pharmaceutical Biotechnology Cardiovascular and Metabolic Effects of Ghrelin
Current Diabetes Reviews Novel Therapeutic Strategies for Fibrotic Lung Disease: A Review with a Focus on Epithelial-Mesenchymal Transition
Recent Patents on Inflammation & Allergy Drug Discovery Gallium-68 in Medical Imaging
Current Radiopharmaceuticals Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Antiviral Activity of Jodantipyrin – An Anti-Inflammatory Oral Therapeutic with Interferon-Inducing Properties
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in pH-Sensitive Polymeric Nanoparticles for Smart Drug Delivery in Cancer Therapy
Current Drug Targets Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets The Possible Use of Terpene Compounds in DC Immunotherapy against Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)